English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Delivery and therapeutic potential of human granzyme B

MPS-Authors
/persons/resource/persons38953

Kurschus,  F. C.
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

/persons/resource/persons38911

Jenne,  D. E.
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

External Ressource
No external resources are shared
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Kurschus, F. C., & Jenne, D. E. (2010). Delivery and therapeutic potential of human granzyme B. Immunological Reviews, 235, 159-171.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0012-1FC0-F
Abstract
Granzyme B (GzmB) is used by cytotoxic lymphocytes as a molecular weapon for the defense against virus-infected and malignantly transformed host cells. It belongs to a family of small serine proteases that are stored in secretory vesicles of killer cells. After secretion of these cytolytic granules during killer cell attack, GzmB is translocated into the cytosol of target cells with the help of the pore-forming protein perforin. GzmB has adopted similar protease specificity as caspase-8, and once delivered, it activates major executioner apoptosis pathways. Since GzmB is very effective in killing human tumor cell lines that are otherwise resistant against many cytotoxic drugs and since GzmB of human origin can be recombinantly expressed, its use as part of a 'magic bullet' in tumor therapy is a very tempting idea. In this review, we emphasize the peculiar characteristics of GzmB that make it suited for use as an effector domain in potential immunoconjugates. We discuss what is known about its uptake into target cells and the trials performed with GzmB-armed immunoconjugates, and we assess the prospects of its potential therapeutic value.